Intellia Therapeutics Stock Forecast
NASDAQ: NTLAHealth CareBiotechnology: In Vitro & In Vivo Diagnostic SubstancesUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
After hours: 12.60 -0.02%
NTLA analyst consensus
Consensus (20 analysts)
buy
Avg. price target
$23.11+83.41%
- Strong buy 1
- Buy 9
- Hold 6
- Sell 2
- Strong sell 2
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 20 Wall Street analysts covering Intellia Therapeutics (2026-10-07), 10 rate the stock a buy or strong buy, 6 rate it a hold and 4 rate it a sell or strong sell, for a consensus rating of "buy". The average 12-month price target is $23.11, with a high estimate of $61.00 and a low estimate of $8.00. The average target implies upside of 83.4% from the current price of $12.60.
The spread between the highest and lowest targets is 662.5%, a wide range that reflects significant disagreement among analysts. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for NTLA.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 1 | 5% |
| Buy | 9 | 45% |
| Hold | 6 | 30% |
| Sell | 2 | 10% |
| Strong sell | 2 | 10% |
Ratings as of 2026-10-07.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $8.00 | -36.51% |
| Average target | $23.11 | +83.41% |
| High target | $61.00 | +384.13% |